MLKL and breast cancer: In the current study with the genetically modified MMTV-PyMT breast cancer model, we have confirmed that blocking necroptosis by deletion of the key necroptosis effector protein, MLKL, dramatically inhibits lung metastasis, but has no or little effect on tumor initiation and growth at the stages of tumor development before necroptosis occurs.